{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:58:34Z","timestamp":1782572314262,"version":"3.54.5"},"reference-count":314,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.lfs.2021.120267","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T11:28:54Z","timestamp":1640863734000},"page":"120267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy"],"prefix":"10.1016","volume":"291","author":[{"given":"Mennatallah O.","family":"Zaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa A.","family":"Elsherbiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar S.","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0005","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","article-title":"A protein factor essential for microtubule assembly","volume":"72","author":"Weingarten","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb0010","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/EBC20180031","article-title":"Microtubule structure by cryo-EM: snapshots of dynamic instability","volume":"62","author":"Manka","year":"2018","journal-title":"Essays Biochem."},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb0015","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41374-019-0197-x","article-title":"MAPT mutations, tauopathy, and mechanisms of neurodegeneration","volume":"99","author":"Strang","year":"2019","journal-title":"Lab. Investig."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb0025","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006247","article-title":"Biochemistry and cell biology of tau protein in neurofibrillary degeneration","volume":"2","author":"Mandelkow","year":"2012","journal-title":"Cold Spring Harbor Perspect. Med."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0030","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.lfs.2021.120267_bb0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2017.05.003","article-title":"Distinct phenotypes of three-repeat and four-repeat human tau in a transgenic model of tauopathy","volume":"105","author":"Sealey","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0040","doi-asserted-by":"crossref","first-page":"40764","DOI":"10.1038\/srep40764","article-title":"Developmental expression of 4-repeat-tau induces neuronal aneuploidy in Drosophila tauopathy models","volume":"7","author":"Malmanche","year":"2017","journal-title":"Sci. Rep."},{"issue":"Pt 3","key":"10.1016\/j.lfs.2021.120267_bb0045","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","article-title":"Tau and tauopathies","volume":"126","author":"Arendt","year":"2016","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0050","doi-asserted-by":"crossref","first-page":"13556","DOI":"10.1038\/s41598-017-13786-2","article-title":"Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects","volume":"7","author":"Lathuiliere","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau protein isoforms, phosphorylation and role in neurodegenerative disorders","volume":"33","author":"Bu\u00e9e","year":"2000","journal-title":"Brain Res. Rev."},{"issue":"17","key":"10.1016\/j.lfs.2021.120267_bb0060","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00018-007-7220-x","article-title":"Tauopathies","volume":"64","author":"Hernandez","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1152\/physrev.00024.2003","article-title":"Role of tau protein in both physiological and pathological conditions","volume":"84","author":"Avila","year":"2004","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.lfs.2021.120267_bb0070","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/151979","article-title":"Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies","volume":"2015","author":"Alavi Naini","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0075","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00115-018-0584-3","article-title":"Tauopathies: from molecule to therapy","volume":"89","author":"Kovacs","year":"2018","journal-title":"Nervenarzt"},{"issue":"21","key":"10.1016\/j.lfs.2021.120267_bb0080","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1021\/jm301079z","article-title":"Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies","volume":"55","author":"Ballatore","year":"2012","journal-title":"J. Med. Chem."},{"issue":"Pt 3","key":"10.1016\/j.lfs.2021.120267_bb0085","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","article-title":"Tau and tauopathies","volume":"126","author":"Arendt","year":"2016","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-017-0303-5","article-title":"Metabolic status of CSF distinguishes rats with tauopathy from controls","volume":"9","author":"Karl\u00edkov\u00e1","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.lfs.2021.120267_bb0095","article-title":"Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease","volume":"2012","author":"Crespo-Biel","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"issue":"9","key":"10.1016\/j.lfs.2021.120267_bb0100","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1021\/cn500143n","article-title":"Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species","volume":"5","author":"Gerson","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"0 1","key":"10.1016\/j.lfs.2021.120267_bb0105","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.parkreldis.2015.09.020","article-title":"Tauopathies as clinicopathological entities","volume":"22","author":"Irwin","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"issue":"8","key":"10.1016\/j.lfs.2021.120267_bb0110","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118664","article-title":"Glycogen synthase kinase-3 signaling in Alzheimer's disease","volume":"1867","author":"Lauretti","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb0120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0022-2836(77)90214-5","article-title":"Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly","volume":"116","author":"Cleveland","year":"1977","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0896-6273(92)90117-V","article-title":"Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms","volume":"8","author":"Goedert","year":"1992","journal-title":"Neuron"},{"issue":"4994","key":"10.1016\/j.lfs.2021.120267_bb0130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.1899488","article-title":"A68: a major subunit of paired helical filaments and derivatized forms of normal tau","volume":"251","author":"Lee","year":"1991","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0135","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0014-5793(02)03611-6","article-title":"The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies","volume":"531","author":"Hanger","year":"2002","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0140","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.neuint.2010.12.023","article-title":"Post-translational modifications of tau protein: implications for Alzheimer's disease","volume":"58","author":"Martin","year":"2011","journal-title":"Neurochem. Int."},{"issue":"11","key":"10.1016\/j.lfs.2021.120267_bb0145","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nrd3869","article-title":"Drug repositioning for Alzheimer's disease","volume":"11","author":"Corbett","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb0150","doi-asserted-by":"crossref","first-page":"758","DOI":"10.2174\/1570159X15666171030142108","article-title":"Combining in vitro and in silico approaches to find new candidate drugs targeting the pathological proteins related to the Alzheimer's disease","volume":"16","author":"Li","year":"2018","journal-title":"Curr. Neuropharmacol."},{"issue":"12","key":"10.1016\/j.lfs.2021.120267_bb0155","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41582-020-0397-4","article-title":"Drug repositioning and repurposing for Alzheimer disease","volume":"16","author":"Ballard","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-020-00662-x","article-title":"Repurposed agents in the Alzheimer's disease drug development pipeline","volume":"12","author":"Bauzon","year":"2020","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0165","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12916-014-0192-4","article-title":"Comorbidity and dementia: a scoping review of the literature","volume":"12","author":"Bunn","year":"2014","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0170","first-page":"33","article-title":"Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data","volume":"46","author":"Clague","year":"2017","journal-title":"Age Ageing"},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0175","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.mcna.2004.04.013","article-title":"Pathogenesis of type 2 diabetes mellitus","volume":"88","author":"DeFronzo","year":"2004","journal-title":"Med. Clin. North Am."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0180","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrm2327","article-title":"Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes","volume":"9","author":"Muoio","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0185","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.arcmed.2005.01.003","article-title":"Pathogenesis of type 2 diabetes mellitus","volume":"36","author":"Leahy","year":"2005","journal-title":"Arch. Med. Res."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0190","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4103\/ajm.ajm_53_20","article-title":"Pathophysiology of diabetes: an overview","volume":"10","author":"Banday","year":"2020","journal-title":"Avicenna J.Med."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0195","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(14)70249-2","article-title":"Cognitive function in patients with diabetes mellitus: guidance for daily care","volume":"14","author":"Koekkoek","year":"2015","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0200","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.3390\/ijms20102539","article-title":"The dipeptidyl peptidase-4 inhibitor linagliptin ameliorates high-fat induced cognitive decline in tauopathy model mice","volume":"20","author":"Nakaoku","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2021.120267_bb0205","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.2147\/DDDT.S173970","article-title":"Mechanism involved in insulin resistance via accumulation of beta-amyloid and neurofibrillary tangles: link between type 2 diabetes and Alzheimer's disease","volume":"12","author":"Rad","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0210","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"Pt B","key":"10.1016\/j.lfs.2021.120267_bb0215","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2013.10.052","article-title":"Glimepiride attenuates Abeta production via suppressing BACE1 activity in cortical neurons","volume":"557","author":"Liu","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.lfs.2021.120267_bb0220","first-page":"684","article-title":"Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease","volume":"14","author":"Rizvi","year":"2015","journal-title":"EXCLI J."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0225","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/187152712800792767","article-title":"Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase","volume":"11","author":"Priyadarshini","year":"2012","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"Pt A","key":"10.1016\/j.lfs.2021.120267_bb0230","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nbd.2014.05.001","article-title":"Early detection of Alzheimer's disease using PiB and FDG PET","volume":"72","author":"Cohen","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.lfs.2021.120267_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.04.070","article-title":"Oxymatrine protects neonatal rat against hypoxic-ischemic brain damage via PI3K\/Akt\/GSK3\u03b2 pathway","volume":"254","author":"Liu","year":"2020","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0240","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00401-014-1328-5","article-title":"Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies","volume":"128","author":"Yarchoan","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"31","key":"10.1016\/j.lfs.2021.120267_bb0245","doi-asserted-by":"crossref","first-page":"19547","DOI":"10.1074\/jbc.272.31.19547","article-title":"Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons","volume":"272","author":"Hong","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb0250","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1471-4159.1999.0720576.x","article-title":"Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase","volume":"72","author":"Lesort","year":"1999","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb0255","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuropharm.2011.01.033","article-title":"Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes","volume":"60","author":"Gupta","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2021.120267_bb0260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fncel.2014.00022","article-title":"Insulin dysfunction and tau pathology","volume":"8","author":"El Khoury","year":"2014","journal-title":"Front. Cell. Neurosci."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb0265","doi-asserted-by":"crossref","first-page":"537","DOI":"10.33549\/physiolres.930111","article-title":"The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas","volume":"50","author":"Szkudelski","year":"2001","journal-title":"Physiol. Res."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0270","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1037\/0735-7044.112.5.1199","article-title":"Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats","volume":"112","author":"Lannert","year":"1998","journal-title":"Behav. Neurosci."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0275","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1471-4159.2006.04368.x","article-title":"Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein","volume":"101","author":"Gr\u00fcnblatt","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2021.120267_bb0280","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fendo.2018.00400","article-title":"The therapeutic potential of metformin in neurodegenerative diseases","volume":"9","author":"Rotermund","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"18","key":"10.1016\/j.lfs.2021.120267_bb0285","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0000000000004586","article-title":"Metformin vs sulfonylurea use and risk of dementia in US veterans aged \u226565 years with diabetes","volume":"89","author":"Orkaby","year":"2017","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0290","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/gerona\/glu073","article-title":"Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis","volume":"69","author":"Cheng","year":"2014","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0295","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3233\/JAD-2011-101524","article-title":"Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin","volume":"24","author":"Hsu","year":"2011","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0300","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb0305","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-150493","article-title":"Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial","volume":"51","author":"Luchsinger","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0310","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","article-title":"Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study","volume":"60","author":"Imfeld","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"issue":"50","key":"10.1016\/j.lfs.2021.120267_bb0315","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1073\/pnas.0912793107","article-title":"Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling","volume":"107","author":"Kickstein","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.120267_bb0320","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.expneurol.2018.09.008","article-title":"Metformin attenuates diabetes-induced tau hyperphosphorylation in vitro and in vivo by enhancing autophagic clearance","volume":"311","author":"Chen","year":"2019","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0325","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pbb.2012.03.002","article-title":"Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice","volume":"101","author":"Li","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.lfs.2021.120267_bb0330","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fncel.2020.00170","article-title":"Metformin ameliorates synaptic defects in a mouse model of AD by inhibiting Cdk5 activity","volume":"14","author":"Wang","year":"2020","journal-title":"Front. Cell. Neurosci."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0335","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3233\/JAD-181240","article-title":"Metformin improves learning and memory in the SAMP8 mouse model of Alzheimer's disease","volume":"68","author":"Farr","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2021.120267_bb0340","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13024-016-0082-7","article-title":"Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy","volume":"11","author":"Barini","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.lfs.2021.120267_bb0345","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2016.04.052","article-title":"Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3\u03b2 pathway in an amyloid \u03b2 protein induced Alzheimer disease mouse model","volume":"783","author":"Qi","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.lfs.2021.120267_bb0350","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1007\/s11064-017-2250-8","article-title":"Liraglutide improves water maze learning and memory performance while reduces hyperphosphorylation of tau and neurofilaments in APP\/PS1\/Tau triple transgenic mice","volume":"42","author":"Chen","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.lfs.2021.120267_bb0355","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainres.2015.12.052","article-title":"The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy","volume":"1634","author":"Hansen","year":"2016","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0360","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3390\/ijms21051746","article-title":"Liraglutide protects against brain amyloid-\u03b2(1\u201342) accumulation in female mice with early Alzheimer's disease-like pathology by partially rescuing oxidative\/nitrosative stress and inflammation","volume":"21","author":"Duarte","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2021.120267_bb0365","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3233\/JAD-130584","article-title":"The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice","volume":"37","author":"Xiong","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2021.120267_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107668","article-title":"DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling","volume":"157","author":"Chen","year":"2019","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.lfs.2021.120267_bb0375","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1007\/s12035-016-0125-7","article-title":"Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer's disease","volume":"54","author":"Kosaraju","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0380","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.nbd.2011.12.043","article-title":"Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures","volume":"46","author":"Kim","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.lfs.2021.120267_bb0385","first-page":"1","article-title":"Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients","author":"De Lorenzo","year":"2021","journal-title":"J. Neurol."},{"issue":"10223","key":"10.1016\/j.lfs.2021.120267_bb0390","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.lfs.2021.120267_bb0395","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0400","first-page":"25","article-title":"Teachers and research in special education","volume":"9","author":"Kiernan","year":"1982","journal-title":"Spec. Educ. Forward Trends"},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb0405","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0410","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.lfs.2021.120267_bb0415","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/bs.aivir.2016.08.004","article-title":"Coronavirus spike protein and tropism changes","volume":"96","author":"Hulswit","year":"2016","journal-title":"Adv. Virus Res."},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb0420","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"issue":"10229","key":"10.1016\/j.lfs.2021.120267_bb0425","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2021.120267_bb0430","series-title":"Characteristics of Lymphocyte Subsets and Cytokines in Peripheral Blood of 123 Hospitalized Patients With 2019 Novel Coronavirus Pneumonia (NCP)","author":"Wan","year":"2020"},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0435","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/nm1007-1142b","article-title":"Not so fast: adaptive suppression of innate immunity","volume":"13","author":"Palm","year":"2007","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb0440","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan,China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol."},{"issue":"23","key":"10.1016\/j.lfs.2021.120267_bb0445","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMc2008597","article-title":"Neurologic features in severe SARS-CoV-2 infection","volume":"382","author":"Helms","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lfs.2021.120267_bb0450","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s00405-020-05965-1","article-title":"Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study","volume":"277","author":"Lechien","year":"2020","journal-title":"Eur. Arch. Otorhinolaryngol."},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb0455","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S1474-4422(21)00168-X","article-title":"Could SARS-CoV-2 cause tauopathy?","volume":"20","author":"Pratt","year":"2021","journal-title":"Lancet. Neurol."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0460","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s13365-020-00868-7","article-title":"Coronaviruses and the central nervous system","volume":"26","author":"Morgello","year":"2020","journal-title":"J. Neurovirol."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0465","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13195-020-00640-3","article-title":"Immediate and long-term consequences of COVID-19 infections for the development of neurological disease","volume":"12","author":"Heneka","year":"2020","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0470","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41392-021-00591-7","article-title":"The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys","volume":"6","author":"Jiao","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0475","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"10223","key":"10.1016\/j.lfs.2021.120267_bb0480","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.lfs.2021.120267_bb0485","doi-asserted-by":"crossref","first-page":"8865","DOI":"10.1096\/fj.201802418R","article-title":"Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC","volume":"33","author":"Siu","year":"2019","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb0490","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1474-4422(14)70017-1","article-title":"Long-term cerebral consequences of sepsis","volume":"13","author":"Widmann","year":"2014","journal-title":"Lancet Neurol."},{"issue":"16","key":"10.1016\/j.lfs.2021.120267_bb0495","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1001\/jama.2010.1553","article-title":"Long-term cognitive impairment and functional disability among survivors of severe sepsis","volume":"304","author":"Iwashyna","year":"2010","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.lfs.2021.120267_bb0500","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018101064","article-title":"Systemic inflammation impairs microglial A\u03b2 clearance through NLRP3 inflammasome","volume":"38","author":"Tejera","year":"2019","journal-title":"EMBO J."},{"issue":"7434","key":"10.1016\/j.lfs.2021.120267_bb0505","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature11729","article-title":"NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice","volume":"493","author":"Heneka","year":"2013","journal-title":"Nature"},{"issue":"7685","key":"10.1016\/j.lfs.2021.120267_bb0510","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature25158","article-title":"Microglia-derived ASC specks cross-seed amyloid-\u03b2 in Alzheimer\u2019s disease","volume":"552","author":"Venegas","year":"2017","journal-title":"Nature"},{"issue":"7784","key":"10.1016\/j.lfs.2021.120267_bb0515","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","article-title":"NLRP3 inflammasome activation drives tau pathology","volume":"575","author":"Ising","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.120267_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101623","article-title":"Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis","volume":"34","author":"Rodriguez-Morales","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"issue":"11","key":"10.1016\/j.lfs.2021.120267_bb0525","doi-asserted-by":"crossref","first-page":"e3170","DOI":"10.1038\/cddis.2017.549","article-title":"Ly6G+ neutrophil-derived miR-223 inhibits the NLRP3 inflammasome in mitochondrial DAMP-induced acute lung injury","volume":"8","author":"Feng","year":"2017","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb0530","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1165\/rcmb.2013-0087OC","article-title":"The NLRP3 inflammasome is required for the development of hypoxemia in LPS\/mechanical ventilation acute lung injury","volume":"50","author":"Jones","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb0535","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/cells10020386","article-title":"Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations","volume":"10","author":"Sun","year":"2021","journal-title":"Cells"},{"issue":"5054","key":"10.1016\/j.lfs.2021.120267_bb0540","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0545","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40035-021-00237-2","article-title":"COVID-19 and Alzheimer\u2019s disease: how one crisis worsens the other","volume":"10","author":"Xia","year":"2021","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.lfs.2021.120267_bb0550","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9171424","article-title":"Theories of aging and the prevalence of Alzheimer's disease","volume":"2019","author":"Trevisan","year":"2019","journal-title":"Biomed. Res. Int."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0555","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41591-020-0822-7","article-title":"Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan,China","volume":"26","author":"Wu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2021.120267_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101205","article-title":"Aging in COVID-19: vulnerability, immunity and intervention","volume":"65","author":"Chen","year":"2021","journal-title":"Ageing Res. Rev."},{"issue":"15","key":"10.1016\/j.lfs.2021.120267_bb0565","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.15.2000448","article-title":"Potential lethal outbreak of coronavirus disease (COVID-19) among the elderly in retirement homes and long-term facilities, France, March 2020","volume":"25","author":"Etard","year":"2020","journal-title":"Euro Surveill"},{"issue":"18","key":"10.1016\/j.lfs.2021.120267_bb0570","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-209004","article-title":"Alzheimer's disease patients in the crosshairs of COVID-19","volume":"76","author":"Perry","year":"2020","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb0580","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jagp.2020.04.010","article-title":"Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer's disease and related dementias","volume":"28","author":"Brown","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0585","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/JAD-200581","article-title":"Neurobiology of COVID-19","volume":"76","author":"Fotuhi","year":"2020","journal-title":"J. Alzheimers Dis."},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0590","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2215-0366(20)30287-X","article-title":"Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study","volume":"7","author":"Varatharaj","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0595","article-title":"COVID-19 pandemic: a neurological perspective","volume":"12","author":"Lahiri","year":"2020","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0600","article-title":"A review of neurological complications of COVID-19","volume":"12","author":"Sheraton","year":"2020","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0605","first-page":"55","article-title":"Study of interleukin-6 production in Alzheimer's disease","volume":"49","author":"Cojocaru","year":"2011","journal-title":"Rom. J. Intern. Med."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0610","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.imlet.2007.09.002","article-title":"Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression","volume":"114","author":"Motta","year":"2007","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.lfs.2021.120267_bb0615","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nlm.2018.06.006","article-title":"IL-6 deficiency alters spatial memory in 4- and 24-month-old mice","volume":"155","author":"Bialuk","year":"2018","journal-title":"Neurobiol. Learn. Mem."},{"issue":"8","key":"10.1016\/j.lfs.2021.120267_bb0620","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1093\/cid\/ciaa449","article-title":"Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019","volume":"71","author":"Chen","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0630","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0197-4580(96)00107-8","article-title":"Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options","volume":"17","author":"H\u00fcll","year":"1996","journal-title":"Neurobiol. Aging"},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb0635","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"32","key":"10.1016\/j.lfs.2021.120267_bb0640","doi-asserted-by":"crossref","first-page":"18951","DOI":"10.1073\/pnas.2009017117","article-title":"Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19","volume":"117","author":"Cauchois","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"19","key":"10.1016\/j.lfs.2021.120267_bb0645","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1073\/pnas.86.19.7611","article-title":"Brain interleukin 1 and S-100 immunoreactivity are elevated in down syndrome and Alzheimer disease","volume":"86","author":"Griffin","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0650","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0197-4580(96)00104-2","article-title":"In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis","volume":"17","author":"Sheng","year":"1996","journal-title":"Neurobiol. Aging"},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0655","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/hipo.10164","article-title":"Learning modulation by endogenous hippocampal IL-1: blockade of endogenous IL-1 facilitates memory formation","volume":"14","author":"Depino","year":"2004","journal-title":"Hippocampus"},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0660","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jinf.2020.06.072","article-title":"Elevation of ACE2 as a SARS-CoV-2 entry receptor gene expression in Alzheimer's disease","volume":"81","author":"Lim","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.lfs.2021.120267_bb0665","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41421-020-0147-1","article-title":"Comparative genetic analysis of the novel coronavirus (2019-nCoV\/SARS-CoV-2) receptor ACE2 in different populations","volume":"6","author":"Cao","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.lfs.2021.120267_bb0670","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bcp.2018.01.047","article-title":"Angiotensin 1\u20137 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor\/PI3K\/Akt\/BDNF pathway and inhibition of angiotensin II type-1 receptor\/NF-\u03baB axis","volume":"151","author":"Rabie","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb0675","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1570159X11311020007","article-title":"ACE2-ang-(1\u20137)-mas Axis in brain: a potential target for prevention and treatment of ischemic stroke","volume":"11","author":"Jiang","year":"2013","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0680","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13195-016-0217-7","article-title":"Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-\u03b2 and tau pathology","volume":"8","author":"Kehoe","year":"2016","journal-title":"Alzheimers Res. Ther."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0685","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(10)70325-2","article-title":"Apolipoprotein E in Alzheimer's disease and other neurological disorders","volume":"10","author":"Verghese","year":"2011","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.lfs.2021.120267_bb0690","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/gerona\/glaa131","article-title":"APOE e4 genotype predicts severe COVID-19 in the UK biobank community cohort","volume":"75","author":"Kuo","year":"2020","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"23","key":"10.1016\/j.lfs.2021.120267_bb0695","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.3390\/ijms20235939","article-title":"Apolipoprotein C1: its pleiotropic effects in lipid metabolism and beyond","volume":"20","author":"Fuior","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.lfs.2021.120267_bb0700","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1212\/01.wnl.0000210447.19748.0b","article-title":"Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers","volume":"66","author":"Beeri","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.lfs.2021.120267_bb0705","doi-asserted-by":"crossref","first-page":"173748","DOI":"10.1016\/j.ejphar.2020.173748","article-title":"A review on possible mechanistic insights of nitazoxanide for repurposing in COVID-19","volume":"891","author":"Lokhande","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0710","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41401-019-0220-1","article-title":"Nitazoxanide, an anti-parasitic drug, efficiently ameliorates learning and memory impairments in AD model mice","volume":"40","author":"Fan","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0715","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.apsb.2019.07.006","article-title":"Discovery of nitazoxanide-based derivatives as autophagy activators for the treatment of Alzheimer's disease","volume":"10","author":"Li","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.lfs.2021.120267_bb0720","first-page":"1","article-title":"Hydroxychloroquine in COVID-19: potential mechanism of action against SARS-CoV-2","author":"Satarker","year":"2020","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.lfs.2021.120267_bb0725","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JAD-2009-0908","article-title":"Inhibition of autophagy causes tau proteolysis by activating calpain in rat brain","volume":"16","author":"Zhang","year":"2009","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0730","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/s13054-020-03158-0","article-title":"Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series","volume":"24","author":"Stallmach","year":"2020","journal-title":"Crit. Care (Lond.Engl.)"},{"key":"10.1016\/j.lfs.2021.120267_bb0735","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.brainres.2010.10.053","article-title":"Anti-TNF-\u03b1 reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP\/PS1 transgenic mouse brains","volume":"1368","author":"Shi","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2021.120267_bb0740","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.bbr.2016.06.001","article-title":"Infliximab ameliorates AD-associated object recognition memory impairment","volume":"311","author":"Kim","year":"2016","journal-title":"Behav. Brain Res."},{"issue":"20","key":"10.1016\/j.lfs.2021.120267_bb0745","first-page":"5394","article-title":"Connecting TNF-\u03b1 signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid \u03b2 protein","volume":"27","author":"Medeiros","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.lfs.2021.120267_bb0750","article-title":"Tumor necrosis factor \u03b1 inhibition for Alzheimer's disease","volume":"9","author":"Chang","year":"2017","journal-title":"J.Cent. Nervous Syst.Dis."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0760","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11010-016-2762-6","article-title":"Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model","volume":"420","author":"Elcio\u011flu","year":"2016","journal-title":"Mol. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0765","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/1932296820924469","article-title":"Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States","volume":"14","author":"Bode","year":"2020","journal-title":"J. Diabetes Sci. Technol."},{"issue":"20","key":"10.1016\/j.lfs.2021.120267_bb0770","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0775","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0780","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/1568010042634488","article-title":"Pulmonary complications in diabetes mellitus: the role of glycemic control","volume":"3","author":"Ardigo","year":"2004","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0785","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cen.14288","article-title":"COVID-19 and diabetes: insulin requirements parallel illness severity in critically unwell patients","volume":"93","author":"Wu","year":"2020","journal-title":"Clin. Endocrinol."},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0790","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.2337\/dbi20-0022","article-title":"Managing hyperglycemia in the COVID-19 inflammatory storm","volume":"69","author":"Gianchandani","year":"2020","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0795","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bpa.2009.08.005","article-title":"Hyperglycaemia as part of the stress response: the underlying mechanisms","volume":"23","author":"Van Cromphaut","year":"2009","journal-title":"Best Pract. Res. Clin. Anaesthesiol."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb0800","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.cmet.2020.04.021","article-title":"Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes","volume":"31","author":"Zhu","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.lfs.2021.120267_bb0805","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis","volume":"94","author":"Yang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"16","key":"10.1016\/j.lfs.2021.120267_bb0810","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region,Italy","volume":"323","author":"Grasselli","year":"2020","journal-title":"Jama"},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0815","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S2213-8587(20)30271-0","article-title":"Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study","volume":"8","author":"Holman","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0820","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cmet.2020.07.007","article-title":"Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1\u03b1\/glycolysis-dependent axis","volume":"32","author":"Codo","year":"2020","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb0825","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan,China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0830","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2337\/dc17-2131","article-title":"Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study","volume":"41","author":"Carey","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0835","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2337\/dc18-0287","article-title":"Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study","volume":"41","author":"Critchley","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0840","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0845","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3892\/ijmm.2014.1917","article-title":"The angiotensin-converting enzyme 2\/angiotensin (1\u20137)\/Mas axis protects the function of pancreatic \u03b2 cells by improving the function of islet microvascular endothelial cells","volume":"34","author":"Lu","year":"2014","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0850","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00592-009-0109-4","article-title":"Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes","volume":"47","author":"Yang","year":"2010","journal-title":"Acta Diabetol."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0855","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-006-1996-6","article-title":"Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan","volume":"42","author":"Ito","year":"2007","journal-title":"J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0860","doi-asserted-by":"crossref","first-page":"G653","DOI":"10.1152\/ajpgi.00404.2018","article-title":"Intestinal serine protease inhibition increases FGF21 and improves metabolism in obese mice","volume":"316","author":"Albarazanji","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb0865","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.metabol.2004.12.005","article-title":"Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats","volume":"54","author":"Jia","year":"2005","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.lfs.2021.120267_bb0870","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2020.1787","article-title":"Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit","volume":"5","author":"Bessi\u00e8re","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"9","key":"10.1016\/j.lfs.2021.120267_bb0875","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0880","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1007\/s00125-015-3689-2","article-title":"Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial","volume":"58","author":"Wasko","year":"2015","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0885","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40618-020-01330-5","article-title":"Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs","volume":"44","author":"Chakravarti","year":"2021","journal-title":"J. Endocrinol. Investig."},{"issue":"20","key":"10.1016\/j.lfs.2021.120267_bb0890","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb0895","first-page":"465","article-title":"Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis","volume":"37","author":"Castaneda","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0900","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yexcr.2004.01.002","article-title":"Interleukin-6 induces alzheimer-type phosphorylation of tau protein by deregulating the cdk5\/p35 pathway","volume":"295","author":"Quintanilla","year":"2004","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0905","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chom.2020.05.007","article-title":"Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis","volume":"28","author":"Dimopoulos","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"15","key":"10.1016\/j.lfs.2021.120267_bb0910","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","article-title":"Interleukin-1-receptor antagonist in type 2 diabetes mellitus","volume":"356","author":"Larsen","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.lfs.2021.120267_bb0915","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/archinte.160.13.2050","article-title":"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study","volume":"160","author":"Tsiodras","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0920","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2337\/diabetes.52.4.918","article-title":"Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens","volume":"52","author":"Woerle","year":"2003","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb0925","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/archinte.165.10.1179","article-title":"Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study","volume":"165","author":"Brown","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"14","key":"10.1016\/j.lfs.2021.120267_bb0930","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/00002030-199910010-00029","article-title":"Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance","volume":"13","author":"Kan","year":"1999","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb0935","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00401-006-0037-0","article-title":"Accelerated tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy","volume":"111","author":"Anthony","year":"2006","journal-title":"Acta Neuropathol."},{"issue":"14","key":"10.1016\/j.lfs.2021.120267_bb0940","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1097\/QAD.0000000000001927","article-title":"Association of antiretroviral therapy with brain aging changes among HIV-infected adults","volume":"32","author":"Soontornniyomkij","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.lfs.2021.120267_bb0945","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diabres.2018.03.006","article-title":"Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review","volume":"139","author":"Bonaventura","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb0950","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1464-5491.2006.01861.x","article-title":"Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS","volume":"23","author":"Yang","year":"2006","journal-title":"Diabet. Med."},{"key":"10.1016\/j.lfs.2021.120267_bb0955","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neurobiolaging.2017.05.010","article-title":"Glucocorticoid-mediated activation of GSK3\u03b2 promotes tau phosphorylation and impairs memory in type 2 diabetes","volume":"57","author":"Dey","year":"2017","journal-title":"Neurobiol. Aging"},{"issue":"35","key":"10.1016\/j.lfs.2021.120267_bb0960","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1523\/JNEUROSCI.2797-06.2006","article-title":"Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease","volume":"26","author":"Green","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2021.120267_bb0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108183","article-title":"Metformin in COVID-19: a possible role beyond diabetes","volume":"164","author":"Sharma","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb0970","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S2213-8587(20)30152-2","article-title":"Practical recommendations for the management of diabetes in patients with COVID-19","volume":"8","author":"Bornstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.lfs.2021.120267_bb0975","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.neuropharm.2013.04.008","article-title":"Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease","volume":"72","author":"Kosaraju","year":"2013","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.lfs.2021.120267_bb0980","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jphp.12148","article-title":"Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease","volume":"65","author":"Kosaraju","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb0985","doi-asserted-by":"crossref","first-page":"102058","DOI":"10.1016\/j.isci.2021.102058","article-title":"Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3\u03b2) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation","volume":"24","author":"Amaral","year":"2021","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb0990","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040721","article-title":"GSK-3 and tau: a key duet in Alzheimer\u2019s disease","volume":"10","author":"Sayas","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb0995","doi-asserted-by":"crossref","first-page":"8187","DOI":"10.1038\/srep08187","article-title":"Truncation and activation of GSK-3\u03b2 by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease","volume":"5","author":"Jin","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1000","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13195-020-00680-9","article-title":"Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer\u2019s disease","volume":"12","author":"Ahmad","year":"2020","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3233\/JAD-160891","article-title":"Autotaxin is related to metabolic dysfunction and predicts Alzheimer's disease outcomes","volume":"56","author":"McLimans","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb1010","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3390\/ijms19071827","article-title":"Autotaxin-lysophosphatidic acid signaling in Alzheimer\u2019s disease","volume":"19","author":"Ramesh","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb1015","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/cells10020262","article-title":"Mechanisms and therapeutic implications of GSK-3 in treating neurodegeneration","volume":"10","author":"Rippin","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1020","first-page":"104","article-title":"Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease","volume":"10","author":"Nunes","year":"2013","journal-title":"Curr. Alzheimer Res."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb1025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3233\/JAD-150437","article-title":"Lithium as a treatment for Alzheimer's disease: a systematic review and meta-analysis","volume":"48","author":"Matsunaga","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb1030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.bp.110.080044","article-title":"Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial","volume":"198","author":"Forlenza","year":"2011","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb1035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3\u03b2 inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo","volume":"35","author":"Seren\u00f3","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.lfs.2021.120267_bb1040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of Tideglusib in Alzheimer's disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J. Alzheimer's Dis."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer's disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2021.120267_bb1050","article-title":"Berberine reduces A\u03b2(42) deposition and tau hyperphosphorylation via ameliorating endoplasmic reticulum stress","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2021.120267_bb1055","doi-asserted-by":"crossref","DOI":"10.1002\/tox.23354","article-title":"Pretreatment with metformin prevents microcystin-LR-induced tau hyperphosphorylation via mTOR-dependent PP2A and GSK-3\u03b2 activation","author":"Zhang","year":"2021","journal-title":"Environ. Toxicol."},{"issue":"9","key":"10.1016\/j.lfs.2021.120267_bb1060","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00726-021-03027-2","article-title":"Epibrassinolide prevents tau hyperphosphorylation via GSK3\u03b2 inhibition in vitro and improves Caenorhabditis elegans lifespan and motor deficits in combination with roscovitine","volume":"53","author":"Obakan Yerlikaya","year":"2021","journal-title":"Amino Acids"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1021\/acschemneuro.0c00617","article-title":"Inhibitory effects of isobavachalcone on tau protein aggregation, tau phosphorylation, and oligomeric tau-induced apoptosis","volume":"12","author":"Xiao","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118664","article-title":"Glycogen synthase kinase-3 signaling in Alzheimer's disease","volume":"1867","author":"Lauretti","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Cell Res."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb1075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/09168451.2018.1549974","article-title":"AKT phosphorylation sites of Ser473 and Thr308 regulate AKT degradation","volume":"83","author":"Wei","year":"2019","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.lfs.2021.120267_bb1080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb1085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb1090","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/mp.2016.214","article-title":"Caspase-3-dependent cleavage of akt modulates tau phosphorylation via GSK3\u03b2 kinase: implications for Alzheimer's disease","volume":"22","author":"Chu","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb1095","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/jnc.13212","article-title":"Activation of Cdk5\/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation","volume":"134","author":"Sun","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2021.120267_bb1100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fnmol.2014.00065","article-title":"Physiological and pathological phosphorylation of tau by Cdk5","volume":"7","author":"Kimura","year":"2014","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb1105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0896-6273(03)00259-9","article-title":"Cdk5 is a key factor in tau aggregation and tangle formation in vivo","volume":"38","author":"Noble","year":"2003","journal-title":"Neuron"},{"issue":"42","key":"10.1016\/j.lfs.2021.120267_bb1110","doi-asserted-by":"crossref","first-page":"13966","DOI":"10.1523\/JNEUROSCI.3637-10.2010","article-title":"Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer's mice","volume":"30","author":"Piedrahita","year":"2010","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb1115","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0896-6273(03)00627-5","article-title":"Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles","volume":"40","author":"Cruz","year":"2003","journal-title":"Neuron"},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb1120","first-page":"135","article-title":"Roscovitine in cancer and other diseases","volume":"3","author":"Cicenas","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"12","key":"10.1016\/j.lfs.2021.120267_bb1125","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","article-title":"Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia","volume":"39","author":"Zeidner","year":"2015","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41418-020-00620-y","article-title":"RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation","volume":"28","author":"Zhao","year":"2021","journal-title":"Cell Death Differ."},{"issue":"15","key":"10.1016\/j.lfs.2021.120267_bb1135","doi-asserted-by":"crossref","first-page":"8096","DOI":"10.3390\/ijms22158096","article-title":"Roscovitine, a cyclin-dependent kinase-5 inhibitor, decreases phosphorylated tau formation and death of retinal ganglion cells of rats after optic nerve crush","volume":"22","author":"Hirokawa","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.lfs.2021.120267_bb1140","doi-asserted-by":"crossref","first-page":"18500","DOI":"10.1039\/C8NJ04306J","article-title":"Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review","volume":"42","author":"Deep","year":"2018","journal-title":"New J. Chem."},{"key":"10.1016\/j.lfs.2021.120267_bb1145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jbiotec.2015.02.032","article-title":"Discovery and development of seliciclib. How systems biology approaches can lead to better drug performance","volume":"202","author":"Khalil","year":"2015","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.lfs.2021.120267_bb1150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.phrs.2016.02.007","article-title":"The antineoplastic drug flavopiridol reverses memory impairment induced by amyloid-\u00df1-42 oligomers in mice","volume":"106","author":"Leggio","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40263-020-00781-x","article-title":"Intranasal insulin for Alzheimer's disease","volume":"35","author":"Hallschmid","year":"2021","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb1160","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s11064-021-03273-6","article-title":"DHCR24 knockdown lead to hyperphosphorylation of tau at Thr181, Thr231, Ser262, Ser396, and Ser422 sites by membrane lipid-raft dependent PP2A signaling in SH-SY5Y cells","volume":"46","author":"Qi","year":"2021","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.lfs.2021.120267_bb1165","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pharmthera.2019.05.016","article-title":"Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration","volume":"201","author":"Clark","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.lfs.2021.120267_bb1170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081871","article-title":"Centella asiatica protects d-galactose\/AlCl3 mediated Alzheimer's disease-like rats via PP2A\/GSK-3beta signaling pathway in their hippocampus","volume":"20","author":"Chiroma","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2021.120267_bb1175","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.595532","article-title":"Tau post-translational modifications: dynamic transformers of tau function, degradation, and aggregation","volume":"11","author":"Alquezar","year":"2021","journal-title":"Front. Neurology"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3233\/JAD-160544","article-title":"A phase IIa randomized control trial of VEL015 (sodium selenate) in mild-moderate Alzheimer's disease","volume":"54","author":"Malpas","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2021.120267_bb1185","doi-asserted-by":"crossref","first-page":"570223","DOI":"10.3389\/fnmol.2020.570223","article-title":"Chronic sodium selenate treatment restores deficits in cognition and synaptic plasticity in a murine model of tauopathy","volume":"13","author":"Ahmed","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb1190","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00213-015-4133-5","article-title":"A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves A\u03b225-35-impaired mouse cognitive function","volume":"233","author":"Zhang","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.lfs.2021.120267_bb1195","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108027","article-title":"SCR-1693 inhibits tau phosphorylation and improves insulin resistance associated cognitive deficits","volume":"168","author":"Bi","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1200","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12974-021-02182-3","article-title":"Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer's disease","volume":"18","author":"Sun","year":"2021","journal-title":"J. Neuroinflamm."},{"issue":"12","key":"10.1016\/j.lfs.2021.120267_bb1205","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.1096\/fj.202001499R","article-title":"Polyphyllin I attenuates cognitive impairments and reduces AD-like pathology through CIP2A-PP2A signaling pathway in 3XTg-AD mice","volume":"34","author":"Zhou","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2021.120267_bb1210","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3389\/fphar.2019.01008","article-title":"Neuroinflammation as a common feature of neurodegenerative disorders","volume":"10","author":"Guzman-Martinez","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.lfs.2021.120267_bb1215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222505","article-title":"Non-steroidal anti-inflammatory drugs use in older adults decreases risk of Alzheimer's disease mortality","volume":"14","author":"Benito-Le\u00f3n","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb1220","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nri.2017.125","article-title":"Microglia and macrophages in brain homeostasis and disease","volume":"18","author":"Li","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb1225","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","article-title":"Differential roles of M1 and M2 microglia in neurodegenerative diseases","volume":"53","author":"Tang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.lfs.2021.120267_bb1230","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer's disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1235","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13024-017-0200-1","article-title":"Absence of CX3CR1 impairs the internalization of tau by microglia","volume":"12","author":"Bol\u00f3s","year":"2017","journal-title":"Mol. Neurodegener."},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb1240","first-page":"7","article-title":"Role of pro-inflammatory cytokines released from microglia in Alzheimer\u2019s disease","volume":"3","author":"Wang","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.lfs.2021.120267_bb1245","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3389\/fimmu.2020.00724","article-title":"TLR4 cross-talk with NLRP3 inflammasome and complement signaling pathways in Alzheimer's disease","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2021.120267_bb1250","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.602508","article-title":"TLR4 targeting as a promising therapeutic strategy for alzheimer disease treatment","volume":"14","author":"Zhou","year":"2020","journal-title":"Front. Neurosci."},{"issue":"Pt 3","key":"10.1016\/j.lfs.2021.120267_bb1255","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/brain\/awv379","article-title":"Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology","volume":"139","author":"Olmos-Alonso","year":"2016","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb1260","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1093\/brain\/awz241","article-title":"CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice","volume":"142","author":"Mancuso","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1265","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13024-018-0244-x","article-title":"Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease","volume":"13","author":"Sosna","year":"2018","journal-title":"Mol. Neurodegener."},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb1270","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/mp.2016.214","article-title":"Caspase-3-dependent cleavage of akt modulates tau phosphorylation via GSK3\u03b2 kinase: implications for Alzheimer\u2019s disease","volume":"22","author":"Chu","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb1275","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008656","article-title":"Caspase functions in cell death and disease","volume":"5","author":"McIlwain","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.lfs.2021.120267_bb1280","first-page":"1910","article-title":"Caspases in the developing central nervous system: apoptosis and beyond","volume":"9","author":"Nguyen","year":"2021","journal-title":"Front. CellDev.Biol."},{"issue":"9","key":"10.1016\/j.lfs.2021.120267_bb1285","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1007\/s11064-016-1942-9","article-title":"Caspase-3-dependent proteolytic cleavage of tau causes neurofibrillary tangles and results in cognitive impairment during normal aging","volume":"41","author":"Means","year":"2016","journal-title":"Neurochem. Res."},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb1290","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.neuron.2015.08.020","article-title":"Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis","volume":"87","author":"Zhao","year":"2015","journal-title":"Neuron"},{"issue":"7292","key":"10.1016\/j.lfs.2021.120267_bb1295","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/nature08890","article-title":"Caspase activation precedes and leads to tangles","volume":"464","author":"de Calignon","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.120267_bb1300","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106549","article-title":"Current druggable targets for therapeutic control of Alzheimer's disease","volume":"109","author":"Gupta","year":"2021","journal-title":"Contemp. Clin. Trials"},{"issue":"24","key":"10.1016\/j.lfs.2021.120267_bb1305","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer's disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb1310","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.lfs.2021.120267_bb1315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052389","article-title":"Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice","volume":"7","author":"Hosokawa","year":"2012","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1320","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer's disease: cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb1330","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/070674371305800702","article-title":"A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments","volume":"58","author":"Cuijpers","year":"2013","journal-title":"Can. J. Psychiatr."},{"issue":"7","key":"10.1016\/j.lfs.2021.120267_bb1335","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1989.03430070062031","article-title":"The functioning and well-being of depressed patients. Results from the Medical Outcomes Study","volume":"262","author":"Wells","year":"1989","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1340","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41398-020-0839-1","article-title":"Depression-an underrecognized target for prevention of dementia in Alzheimer's disease","volume":"10","author":"Dafsari","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb1345","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1590\/1414-431X20133275","article-title":"Changes in tau phosphorylation levels in the hippocampus and frontal cortex following chronic stress","volume":"47","author":"Yang","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.lfs.2021.120267_bb1350","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3389\/fnagi.2018.00383","article-title":"Levels of cortisol in CSF are associated with SNAP-25 and tau pathology but not amyloid-\u03b2","volume":"10","author":"Wang","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.lfs.2021.120267_bb1355","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.exger.2019.05.007","article-title":"Neuropsychological assessment and cortisol levels in biofluids from early Alzheimer's disease patients","volume":"123","author":"Pe\u00f1a-Bautista","year":"2019","journal-title":"Exp. Gerontol."},{"issue":"287","key":"10.1016\/j.lfs.2021.120267_bb1360","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fpsyt.2019.00287","article-title":"Regulation of tau protein on the antidepressant effects of ketamine in the chronic unpredictable mild stress model","volume":"10","author":"Wen","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.lfs.2021.120267_bb1365","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108218","article-title":"The antidepressant drug; trazodone inhibits tau amyloidogenesis: prospects for prophylaxis and treatment of AD","volume":"679","author":"Akbari","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb1370","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3233\/JAD-191078","article-title":"Depression is associated with tau and not amyloid positron emission tomography in cognitively normal adults","volume":"74","author":"Babulal","year":"2020","journal-title":"J. Alzheimers Dis."},{"issue":"S4","key":"10.1016\/j.lfs.2021.120267_bb1375","doi-asserted-by":"crossref","DOI":"10.1002\/alz.039495","article-title":"Level of plasma tau and depression, anxiety and worry in cognitively normal older adults","volume":"16","author":"Hall","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.lfs.2021.120267_bb1380","series-title":"Reviews on New Drug Targets in Age-related Disorders","first-page":"267","article-title":"The challenge of antidepressant therapeutics in Alzheimer's disease","author":"Lozupone","year":"2020"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1385","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.expneurol.2007.01.037","article-title":"Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice","volume":"205","author":"Nelson","year":"2007","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1390","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-020-00194-2","article-title":"Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimer's disease mice","volume":"9","author":"Ai","year":"2020","journal-title":"Transl. Neurodegener."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1395","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1567205017666200213095419","article-title":"Fluoxetine protects against dendritic spine loss in middle-aged APPswe\/PSEN1dE9 double transgenic Alzheimer's disease mice","volume":"17","author":"Ma","year":"2020","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.lfs.2021.120267_bb1400","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fnagi.2018.00164","article-title":"The role of fluoxetine in activating Wnt\/\u03b2-catenin signaling and repressing \u03b2-amyloid production in an Alzheimer mouse model","volume":"10","author":"Huang","year":"2018","journal-title":"Front. Aging Neurosci."},{"issue":"12","key":"10.1016\/j.lfs.2021.120267_bb1405","doi-asserted-by":"crossref","first-page":"13328","DOI":"10.18632\/oncotarget.7798","article-title":"Escitalopram attenuates \u03b2-amyloid-induced tau hyperphosphorylation in primary hippocampal neurons through the 5-HT1A receptor mediated Akt\/GSK-3\u03b2 pathway","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb1410","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3233\/JAD-200401","article-title":"Escitalopram alleviates Alzheimer's disease-type tau pathologies in the aged P301L tau transgenic mice","volume":"77","author":"Wang","year":"2020","journal-title":"J. Alzheimers Dis."},{"issue":"14","key":"10.1016\/j.lfs.2021.120267_bb1415","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1080\/14656566.2020.1781092","article-title":"Treatment strategies for isolated systolic hypertension in elderly patients","volume":"21","author":"Angeli","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb1420","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/HYP.0000000000000053","article-title":"Impact of hypertension on cognitive function: a scientific statement from the American Heart Association","volume":"68","author":"Iadecola","year":"2016","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb1425","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41581-021-00430-6","article-title":"Hypertension-induced cognitive impairment: from pathophysiology to public health","volume":"17","author":"Ungvari","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb1430","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000264828","article-title":"Hypertension increases the probability of Alzheimer's disease and of mild cognitive impairment in an Arab community in northern Israel","volume":"34","author":"Israeli-Korn","year":"2010","journal-title":"Neuroepidemiology"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1435","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0197-4580(00)00106-8","article-title":"Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS.Honolulu-Asia aging study","volume":"21","author":"Petrovitch","year":"2000","journal-title":"Neurobiol Aging"},{"issue":"8","key":"10.1016\/j.lfs.2021.120267_bb1440","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaneurol.2018.0975","article-title":"Assessment of extent and role of tau in subcortical vascular cognitive impairment using 18F-AV1451 positron emission tomography imaging","volume":"75","author":"Kim","year":"2018","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb1445","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00210-016-1234-6","article-title":"Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxido-nitrosative stress","volume":"389","author":"Ali","year":"2016","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.lfs.2021.120267_bb1450","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/917156","article-title":"Inhibition of ACE retards tau hyperphosphorylation and signs of neuronal degeneration in aged rats subjected to chronic mild stress","volume":"2015","author":"AbdAlla","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb1455","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s11481-016-9703-8","article-title":"Angiotensin converting enzyme inhibitors ameliorate brain inflammation associated with microglial activation: possible implications for Alzheimer's disease","volume":"11","author":"Torika","year":"2016","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb1460","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/bph.12177","article-title":"Angiotensin II causes imbalance between pro- and anti-inflammatory cytokines by modulating GSK-3\u03b2 in neuronal culture","volume":"169","author":"Agarwal","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"20","key":"10.1016\/j.lfs.2021.120267_bb1465","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1016\/j.febslet.2012.09.004","article-title":"Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains","volume":"586","author":"Tian","year":"2012","journal-title":"FEBS Lett."},{"issue":"9","key":"10.1016\/j.lfs.2021.120267_bb1470","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamaneurol.2015.1001","article-title":"Association between angiotensin receptor blockers and longitudinal decline in tau in mild cognitive impairment","volume":"72","author":"Hajjar","year":"2015","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.lfs.2021.120267_bb1475","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.023","article-title":"Telmisartan reduces progressive accumulation of cellular amyloid beta and phosphorylated tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat","volume":"23","author":"Kurata","year":"2014","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"2","key":"10.1016\/j.lfs.2021.120267_bb1480","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3233\/JAD-131679","article-title":"Losartan-induced hypotension leads to tau hyperphosphorylation and memory deficit","volume":"40","author":"Liu","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2021.120267_bb1485","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3233\/JAD-170101","article-title":"The rationale and design of the reducing pathology in Alzheimer's disease through angiotensin TaRgeting (RADAR) trial","volume":"61","author":"Kehoe","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2021.120267_bb1490","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.628403","article-title":"Systemic candesartan treatment modulates behavior, synaptic protein levels, and neuroinflammation in female mice that express human APOE4","volume":"15","author":"Scheinman","year":"2021","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1495","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13195-021-00778-8","article-title":"The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE \u03b54 carrier status","volume":"13","author":"Ouk","year":"2021","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1500","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12929-019-0524-y","article-title":"Alzheimer's disease: risk factors and potentially protective measures","volume":"26","author":"Silva","year":"2019","journal-title":"J. Biomed. Sci."},{"issue":"Suppl 2","key":"10.1016\/j.lfs.2021.120267_bb1505","first-page":"S130","article-title":"Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis","volume":"36","author":"McLaurin","year":"2003","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb1510","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3892\/ijmm.2013.1233","article-title":"Hypercholesterolemia accelerates amyloid \u03b2-induced cognitive deficits","volume":"31","author":"Park","year":"2013","journal-title":"Int. J. Mol. Med."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb1515","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","article-title":"Brain metabolic dysfunction at the core of Alzheimer's disease","volume":"88","author":"de la Monte","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2021.120267_bb1520","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0404.2006.00687.x","article-title":"Re-assessing the relationship between cholesterol, statins and Alzheimer's disease","volume":"185","author":"Wolozin","year":"2006","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.lfs.2021.120267_bb1525","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-0404.2006.00691.x","article-title":"Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease","volume":"185","author":"H\u00f6glund","year":"2006","journal-title":"Acta Neurol. Scand. Suppl."},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1530","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13195-017-0237-y","article-title":"Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease","volume":"9","author":"Geifman","year":"2017","journal-title":"Alzheimers Res. Ther."},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb1535","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/clc.22361","article-title":"Cholesterol, statins, and dementia: what the cardiologist should know","volume":"38","author":"Wanamaker","year":"2015","journal-title":"Clin. Cardiol."},{"issue":"6","key":"10.1016\/j.lfs.2021.120267_bb1540","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/glia.22974","article-title":"Simvastatin and atorvastatin facilitates amyloid \u03b2-protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK\/Erk1\/2 pathways","volume":"64","author":"Yamamoto","year":"2016","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.lfs.2021.120267_bb1545","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12883-016-0533-3","article-title":"Atorvastatin in improvement of cognitive impairments caused by amyloid \u03b2 in mice: involvement of inflammatory reaction","volume":"16","author":"Zhao","year":"2016","journal-title":"BMC Neurol."},{"issue":"12","key":"10.1016\/j.lfs.2021.120267_bb1550","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.lfs.2021.120267_bb1555","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archneur.62.5.753","article-title":"Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results","volume":"62","author":"Sparks","year":"2005","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.lfs.2021.120267_bb1560","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.stem.2018.12.013","article-title":"Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-\u03b2 in iPSC-derived Alzheimer's disease neurons","volume":"24","author":"van der Kant","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.lfs.2021.120267_bb1565","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3233\/JAD-2006-10408","article-title":"Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid","volume":"10","author":"Riekse","year":"2006","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2021.120267_bb1570","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3233\/JAD-2006-10409","article-title":"Preservation of the blood brain barrier integrity may underlie neuroprotective effects of statins in Alzheimer's disease","volume":"10","author":"Ghribi","year":"2006","journal-title":"J. Alzheimers Dis."},{"issue":"16","key":"10.1016\/j.lfs.2021.120267_bb1575","article-title":"Neuroprotective effects of ezetimibe versus simvastatin in Alzheimer's induced dementia: perspectives from female rats. (P5.205)","volume":"86","author":"KhalafAllah","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.lfs.2021.120267_bb1580","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40035-018-0110-3","article-title":"The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms","volume":"7","author":"Schultz","year":"2018","journal-title":"Transl. Neurodegener."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521012546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521012546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:58:06Z","timestamp":1758401886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521012546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":314,"alternative-id":["S0024320521012546"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.120267","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.120267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120267"}}